About Cybin
Cybin is a company based in Toronto (Canada) founded in 2002 by Eric So. It operates as a HealthTech. The company has 50 employees as of March 31, 2024. Cybin has completed 2 acquisitions, including Adelia Therapeutics and Small Pharma. Cybin offers products and services including CYB003, CYB004, and CYB005. Cybin operates in a competitive market with competitors including ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Psylo, among others.
- Headquarter Toronto, Canada
- Employees 50 as on 31 Mar, 2024
- Founders Eric So
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cybin, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$78.63 M (USD)-44.9as on Mar 31, 2024
-
EBITDA
-$99.16 M (USD)-81.95as on Mar 31, 2024
-
Latest Funding Round
$50 M (USD), Post-IPO
Jun 30, 2025
-
Investors
Deep Track Capital
& 1 more
-
Employee Count
50
as on Mar 31, 2024
-
Investments & Acquisitions
Adelia Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cybin
Cybin is a publicly listed company on the NEO with ticker symbol CYBN in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cybin
Cybin offers a comprehensive portfolio of products and services, including CYB003, CYB004, and CYB005.
Therapy developed for Major Depressive Disorder treatment.
Therapy designed for Generalized Anxiety Disorder treatment.
Therapy targeting CNS disorders under active development.
People of Cybin
Unlock access to complete
Unlock access to complete
Funding Insights of Cybin
Investors in Cybin
Cybin has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Deep Track Capital and High Trail Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Locked | Locked | Locked | |
|
High Trail Capital is engaged in investment management services.
|
Locked | Locked | Locked |
Investor details for Cybin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cybin
Cybin has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Adelia Therapeutics and Small Pharma.
Investment portfolio details for Cybin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Proprietary psychedelics-based therapeutics for neurodegenerative diseases are developed.
|
Locked | Locked | 2020 | Locked | |
|
Psychedelic-based therapeutics for mental health conditions are developed.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Cybin
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cybin
Detailed financials for Cybin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cybin Comparisons
Peer comparison for Cybin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cybin
Cybin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Psylo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Therapies for mental disorders, including psilocybin for depression, are developed.
|
|
| Locked | Locked | Locked |
Psychedelic-based therapies for brain health disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of neurological and psychiatric disorders
|
|
| Locked | Locked | Locked |
Psychedelic-derived therapeutics for mental illnesses are developed.
|
Detailed competitors of Cybin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cybin
Complete news archive for Cybin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cybin
Cybin was founded in 2002 and raised its 1st funding round 18 years after it was founded.
Cybin is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
As of Mar 31, 2024, the latest employee count at Cybin is 50.
Cybin is engaged in the development of novel neuropsychiatry therapies aimed at transforming mental health treatment. The company is involved in creating proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches. Therapies such as CYB003 for Major Depressive Disorder, CYB004 for Generalized Anxiety Disorder, and CYB005 for CNS disorders are being developed. Partnerships with world-renowned pioneers and a focus on tryptamine-based therapies are maintained to address unmet needs in mental health. The sector of operation includes biotechnology with a specific emphasis on neuropsychiatry solutions.
Cybin's top competitors include MindMed, COMPASS Pathways and Beckley Psytech.
Cybin offers CYB003, CYB004, and CYB005.
Yes, Cybin is publicly traded on NEO under the ticker symbol CYBN.
Cybin has made 2 acquisitions, including Adelia Therapeutics, and Small Pharma.
Cybin has 2 investors. Key investors include Deep Track Capital, and High Trail Capital.
The ticker symbol of Cybin is CYBN on NEO.